Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 19209957
Feldman ME, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7, e38 19209957
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin no effect upon treatment-induced increase
PP30 insulin inhibit treatment-induced increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase

T36-p - 4E-BP1 (mouse)
Modsite: PPGDysttPGGtLFs SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (mouse) no effect upon treatment-induced decrease
PIK90 insulin inhibit treatment-induced increase
PIK90 Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- augment decrease
rapamycin insulin inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
insulin increase treatment in vivo, fat, skeletal muscle. and liver, decrease in fat tissue
PP242 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase modest inhibition

T45-p - 4E-BP1 (mouse)
Modsite: GGtLFsttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (mouse) no effect upon treatment-induced decrease
PIK90 insulin inhibit treatment-induced increase
PIK90 Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- augment decrease
rapamycin insulin inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
insulin increase treatment in vivo, fat, skeletal muscle. and liver, decrease in fat tissue
PP242 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase modest inhibition

S64-p - 4E-BP1 (mouse)
Modsite: FLMECRNsPVAKtPP SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p, 4E‑BP1 (cow): S65‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (mouse) no effect upon treatment-induced decrease
PIK90 insulin inhibit treatment-induced increase
PIK90 Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- augment decrease
rapamycin insulin inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) augment treatment-induced decrease Sin1 -/- inhibit decrease
insulin increase treatment in vivo in fat, skeletal muscle, and liver
PP242 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase

T308-p - Akt1 (mouse)
Modsite: KDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin Sin1 (mouse) no change compared to control SIN1 -/- MEFs
insulin Sin1 (mouse) increase
PP242 insulin no effect upon treatment-induced increase
PIK90 insulin Sin1 (mouse) inhibit treatment-induced increase
BX795 insulin Sin1 (mouse) inhibit treatment-induced increase
rapamycin insulin Sin1 (mouse) no effect upon treatment-induced increase
insulin increase treatment in vivo, fat, skeletal muscle, and liver
PP242 insulin inhibit treatment-induced increase
rapamycin insulin augment treatment-induced increase

T450-p - Akt1 (mouse)
Modsite: TAQMITItPPDQDDS SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T450‑p, Akt1 iso2 (human): T388‑p, Akt1 (mouse): T450‑p, Akt1 (rat): T450‑p, Akt1 (fruit fly): T565‑p, Akt1 (cow): T450‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Sin1 (mouse) no change compared to control SIN1 -/- MEFs no change
insulin Sin1 (mouse) no change compared to control
PP242 insulin Sin1 (mouse) no change compared to control
PIK90 insulin Sin1 (mouse) no change compared to control
BX795 insulin Sin1 (mouse) no change compared to control
rapamycin insulin Sin1 (mouse) no effect upon treatment-induced increase

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
Sin1 (mouse) no change compared to control SIN1 -/- MEFs no change
insulin Sin1 (mouse) no change compared to control
PP242 insulin Sin1 (mouse) no change compared to control
PIK90 insulin Sin1 (mouse) no change compared to control
BX795 insulin Sin1 (mouse) no change compared to control
rapamycin insulin Sin1 (mouse) no effect upon treatment-induced increase
insulin increase treatment in vivo, fat, skeletal muscle, and liver
PP242 insulin inhibit treatment-induced increase
rapamycin insulin augment treatment-induced increase

T24-p - FOXO1A (mouse)
Modsite: LPRQRSCtWPLPRPE SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse

T32-p - FOXO3A (mouse)
Modsite: QSRPRSCtWPLQRPE SwissProt Entrez-Gene
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse

S21-p - GSK3A (mouse)
Modsite: sGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse

S9-p - GSK3B (mouse)
Modsite: SGRPRttsFAEsCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse

T412-p - p70S6K (mouse)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (human) no effect upon treatment-induced decrease Sin1 -/- no effect
PIK90 insulin inhibit treatment-induced increase
insulin, PIK90 Sin1 (mouse) no effect upon treatment-induced decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) no effect upon treatment-induced decrease Sin1 -/- no effect
rapamycin BX795, insulin Sin1 (mouse) inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) no effect upon treatment-induced decrease

S240-p - S6 (mouse)
Modsite: RLssLRAstsKsEss SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (human) no effect upon treatment-induced decrease Sin1 -/- no effect
PIK90 insulin inhibit treatment-induced increase
insulin, PIK90 Sin1 (mouse) no effect upon treatment-induced decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) no effect upon treatment-induced decrease Sin1 -/- no effect
rapamycin BX795, insulin Sin1 (mouse) inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) no effect upon treatment-induced decrease
insulin increase treatment in vivo in fat, skeletal muscle, and liver
PP242 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase

S244-p - S6 (mouse)
Modsite: LRAstsKsEssQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
BX795 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin, PP242 Sin1 (human) no effect upon treatment-induced decrease Sin1 -/- no effect
PIK90 insulin inhibit treatment-induced increase
insulin, PIK90 Sin1 (mouse) no effect upon treatment-induced decrease
BX795 insulin inhibit treatment-induced increase
BX795, insulin Sin1 (mouse) no effect upon treatment-induced decrease Sin1 -/- no effect
rapamycin BX795, insulin Sin1 (mouse) inhibit treatment-induced increase
insulin, rapamycin Sin1 (mouse) no effect upon treatment-induced decrease
insulin increase treatment in vivo in fat, skeletal muscle, and liver
PP242 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase

T1465-p - TSC2 (mouse)
Modsite: GLRPRGYtISDSAPS SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  MEF (fibroblast) [Sin1 (mouse), homozygous knockout]
Cellular systems studied:  primary cells
Species studied:  mouse

T36-p - 4E-BP1 (rat)
Modsite: PPGDYsttPGGtLFS SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T37‑p, 4E‑BP1 (mouse): T36‑p, 4E‑BP1 (rat): T36‑p, 4E‑BP1 (fruit fly): T37‑p, 4E‑BP1 (cow): T37‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin no effect upon treatment-induced increase

T45-p - 4E-BP1 (rat)
Modsite: GGtLFSttPGGtRII SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): T46‑p, 4E‑BP1 (mouse): T45‑p, 4E‑BP1 (rat): T45‑p, 4E‑BP1 (fruit fly): T46‑p, 4E‑BP1 (cow): T46‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin no effect upon treatment-induced increase

S64-p - 4E-BP1 (rat)
Modsite: FLMECRNsPVAKtPP SwissProt Entrez-Gene
Orthologous residues
4E‑BP1 (human): S65‑p, 4E‑BP1 (mouse): S64‑p, 4E‑BP1 (rat): S64‑p, 4E‑BP1 (fruit fly): S65‑p, 4E‑BP1 (cow): S65‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase

T308-p - Akt1 (rat)
Modsite: KDGATMKtFCGTPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PP30 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase inhibits 24 hour treatment, but not 30 min

T450-p - Akt1 (rat)
Modsite: TAQMITItPPDQDDS SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T450‑p, Akt1 iso2 (human): T388‑p, Akt1 (mouse): T450‑p, Akt1 (rat): T450‑p, Akt1 (fruit fly): T565‑p, Akt1 (cow): T450‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin no effect upon treatment-induced increase
PIK90 insulin no effect upon treatment-induced increase
rapamycin insulin inhibit treatment-induced increase

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
PP30 insulin inhibit treatment-induced increase
PIK90 insulin inhibit treatment-induced increase
rapamycin insulin inhibit treatment-induced increase inhibits 24 hour treatment, but not 30 min

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase

Y205-p - ERK1 (rat)
Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase

T183-p - ERK2 (rat)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase

Y185-p - ERK2 (rat)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin no effect upon treatment-induced increase

T24-p - FOXO1A (rat)
Modsite: LPRQRSCtWPLPRPE SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

T32-p - FOXO3A (rat)
Modsite: QSRPRSCtWPLQRPE SwissProt Entrez-Gene
Orthologous residues
FOXO3A (human): T32‑p, FOXO3A (mouse): T32‑p, FOXO3A (rat): T32‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

S21-p - GSK3A (rat)
Modsite: SGRARtssFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

S9-p - GSK3B (rat)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

T412-p - p70S6K (rat)
Modsite: NQVFLGFtYVAPSVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase

S235-p - S6 (rat)
Modsite: IAKRRRLssLRAsts SwissProt Entrez-Gene
Orthologous residues
S6 (human): S235‑p, S6 (mouse): S235‑p, S6 (rat): S235‑p, S6 (fruit fly): A234‑p, S6 (cow): S235‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase

S236-p - S6 (rat)
Modsite: AKRRRLssLRAstsK SwissProt Entrez-Gene
Orthologous residues
S6 (human): S236‑p, S6 (mouse): S236‑p, S6 (rat): S236‑p, S6 (fruit fly): S235‑p, S6 (cow): S236‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase

S240-p - S6 (rat)
Modsite: RLssLRAstsKsESs SwissProt Entrez-Gene
Orthologous residues
S6 (human): S240‑p, S6 (mouse): S240‑p, S6 (rat): S240‑p, S6 (fruit fly): S239‑p, S6 (cow): S240‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase

S244-p - S6 (rat)
Modsite: LRAstsKsESsQK__ SwissProt Entrez-Gene
Orthologous residues
S6 (human): S244‑p, S6 (mouse): S244‑p, S6 (rat): S244‑p, S6 (fruit fly): V243‑p, S6 (cow): S244‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
PP242 insulin inhibit treatment-induced increase
insulin increase
rapamycin insulin inhibit treatment-induced increase

T1466-p - TSC2 (rat)
Modsite: GLRPRGYtISDSAPS SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  L6 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase modest inhibition
PP242 insulin no effect upon treatment-induced increase modest inhibition
PIK90 insulin inhibit treatment-induced increase
API-2 insulin inhibit treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase